



Phenytoin (304): sc-57974

BACKGROUND

Phenytoin is clinically used as an antiepileptic on patients with seizures. It functions in the motor cortex by stabilizing the threshold against hyperexcitability caused by excessive stimulation or environmental changes that reduce the membrane sodium gradient, thereby dampening unwanted brain activity. Phenytoin is mainly excreted in the bile as inactive metabolites which are then reabsorbed in the intestinal tract and excreted in the urine. Phenytoin overdose can cause sedation, cerebellar ataxia and ophthalmoparesis, as well as paradoxical seizures. Phenytoin also commonly causes gingival hyperplasia due to folate deficiency. It may accumulate in the cerebral cortex over long periods of time, and may cause atrophy of the cerebellum when administered at chronically high levels. Despite these risks, Phenytoin has a long history of safe use.

REFERENCES

1. Spector, R.H., Davidoff, R.A. and Schwartzman, R.J. 1976. Phenytoin-induced ophthalmoplegia. *Neurology* 26: 1031-1034.
2. Donovan, P.J. and Cline, D. 1991. Phenytoin administration by constant intravenous infusion: selective rates of administration. *Ann. Emerg. Med.* 20: 139-142.
3. Phillips, N.K. and Lockard, J.S. 1994. Phenytoin and/or stiripentol in pregnancy: infant monkey hyperexcitability. *Epilepsia* 34: 1117-1122.
4. Keele, N.B. 2001. Phenytoin inhibits isolation-induced aggression specifically in serotonin. *Neuroreport* 12: 1107-1112.
5. Blain, H., Hamdan, K.A., Blain, A. and Jeandel, C. 2002. Aplastic anemia induced by Phenytoin: a geriatric case with severe folic acid deficiency. *J. Am. Geriatr. Soc.* 50: 396-397.
6. Takada, K., Sugiyama, H., Umezawa, K., Mega, J. and Hirasawa, M. 2003. The subgingival microflora in Phenytoin-induced gingival hyperplasia. *J. Periodont. Res.* 38: 477-481.
7. Wang, X. and Patsalos, P.N. 2003. A comparison of central brain (cerebrospinal and extracellular fluids) and peripheral blood kinetics of Phenytoin after intravenous Phenytoin and fosphenytoin. *Seizure* 12: 330-336.
8. Scheinfeld, N. 2004. Impact of Phenytoin therapy on the skin and skin disease. *Expert Opin. Drug Saf.* 3: 655-665.
9. Meyer, R.P., Hagemeyer, C.E., Knoth, R., Kaufmann, M.R. and Volk, B. 2005. Anti-epileptic drug Phenytoin enhances androgen metabolism and androgen receptor expression in murine hippocampus. *J. Neurochem.* 96: 460-472.

SOURCE

Phenytoin (304) is a mouse monoclonal antibody raised against Phenytoin.

PRODUCT

Each vial contains 100 µl ascites containing IgG₁ with < 0.1% sodium azide.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

APPLICATIONS

Phenytoin (304) is recommended for detection of Phenytoin by solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

STORAGE

For immediate and continuous use, store at 4° C for up to one month. For sporadic use, freeze in working aliquots in order to avoid repeated freeze/thaw cycles. If turbidity is evident upon prolonged storage, clarify solution by centrifugation.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.